Evercore Wealth Management LLC Buys 223 Shares of Edwards Lifesciences Co. (NYSE:EW)

Evercore Wealth Management LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EWFree Report) by 6.8% during the 4th quarter, Holdings Channel reports. The firm owned 3,485 shares of the medical research company’s stock after acquiring an additional 223 shares during the period. Evercore Wealth Management LLC’s holdings in Edwards Lifesciences were worth $266,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in EW. Janney Montgomery Scott LLC boosted its position in shares of Edwards Lifesciences by 5.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 74,488 shares of the medical research company’s stock worth $5,161,000 after purchasing an additional 3,750 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Edwards Lifesciences by 4.0% during the third quarter. HighTower Advisors LLC now owns 163,296 shares of the medical research company’s stock worth $11,315,000 after acquiring an additional 6,344 shares in the last quarter. Deutsche Bank AG lifted its holdings in Edwards Lifesciences by 41.7% during the third quarter. Deutsche Bank AG now owns 2,744,276 shares of the medical research company’s stock worth $190,123,000 after acquiring an additional 807,502 shares in the last quarter. Ellevest Inc. lifted its holdings in Edwards Lifesciences by 6.9% during the third quarter. Ellevest Inc. now owns 6,605 shares of the medical research company’s stock worth $458,000 after acquiring an additional 426 shares in the last quarter. Finally, Nemes Rush Group LLC lifted its holdings in Edwards Lifesciences by 9.0% during the third quarter. Nemes Rush Group LLC now owns 52,242 shares of the medical research company’s stock worth $3,619,000 after acquiring an additional 4,301 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 2.3 %

NYSE EW opened at $86.10 on Tuesday. The business has a fifty day moving average price of $88.19 and a two-hundred day moving average price of $83.38. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The stock has a market capitalization of $51.88 billion, a PE ratio of 37.11, a PEG ratio of 3.22 and a beta of 1.11.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 14,500 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $91.01, for a total value of $1,319,645.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $3,595,168.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 14,500 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $91.01, for a total transaction of $1,319,645.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at approximately $3,595,168.03. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bernard J. Zovighian sold 8,617 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the transaction, the chief executive officer now directly owns 68,218 shares of the company’s stock, valued at $5,981,354.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,604 shares of company stock worth $12,149,409. Insiders own 1.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Oppenheimer lifted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Citigroup upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $98.00 to $105.00 in a report on Wednesday, May 22nd. Evercore ISI reduced their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a report on Friday, April 26th. Finally, The Goldman Sachs Group initiated coverage on Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $95.06.

View Our Latest Report on Edwards Lifesciences

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.